Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018 - PubMed
5 hours ago
- #MRI
- #CEUS
- #HCC
- Study compares perfluorobutane (PFB) contrast-enhanced US (CEUS) and MRI for diagnosing small hepatocellular carcinoma (HCC) in high-risk patients.
- Two CEUS strategies were evaluated: Strategy A followed LR-5 criteria, while Strategy B expanded to include Kupffer-phase findings.
- Strategy B showed higher sensitivity (65.9%) than Strategy A (57.1%) without significant loss in specificity (91.8% vs 93.9%).
- PFB CEUS demonstrated diagnostic performance similar to MRI, with no significant difference in sensitivity or specificity.
- Specificity was higher in patients without cirrhosis compared to those with cirrhosis for both CEUS strategies.